M
Michael Melchart
Researcher at University of Edinburgh
Publications - 15
Citations - 2265
Michael Melchart is an academic researcher from University of Edinburgh. The author has contributed to research in topics: Ruthenium & Aquation. The author has an hindex of 14, co-authored 15 publications receiving 2133 citations. Previous affiliations of Michael Melchart include Academy of Sciences of the Czech Republic & Western General Hospital.
Papers
More filters
Journal ArticleDOI
Organometallic chemistry, biology and medicine: ruthenium arene anticancer complexes
TL;DR: Initial studies on amino acids and nucleotides suggest that kinetic and thermodynamic control over a wide spectrum of reactions of Ru(II) arene complexes with biomolecules can be achieved.
Journal ArticleDOI
Structure-activity relationships for cytotoxic ruthenium(II) arene complexes containing N,N-, N,O-, and O,O-chelating ligands
Abraha Habtemariam,Michael Melchart,Rafael Fernández,Simon Parsons,Iain D. H. Oswald,Andrew Parkin,Francesca P. A. Fabbiani,James E. Davidson,Alice Dawson,Rhona Aird,Duncan I. Jodrell,Peter J. Sadler +11 more
TL;DR: In this paper, structure-activity relationships for organometallic RuII complexes of the type [(η6-arene)Ru(XY)Cl]Z, where XY is an N,N- (diamine), N,O- (e.g., amino acidate), or O,O − (β-diketonate) chelating ligand, the arene ranges from benzene derivatives to fused polycyclic hydrocarbons, and Z is usually PF6.
Journal ArticleDOI
Controlling ligand substitution reactions of organometallic complexes: tuning cancer cell cytotoxicity.
Fuyi Wang,Abraha Habtemariam,E P L van der Geer,Rafael Fernández,Michael Melchart,Robert J. Deeth,Rhona Aird,Sylvie Guichard,Francesca P. A. Fabbiani,P Lozano-Casal,Iain D. H. Oswald,Duncan I. Jodrell,Simon Parsons,Peter J. Sadler +13 more
TL;DR: The ability to tune the chemical reactivity of this class of organometallic ruthenium arene compounds should be useful in optimizing their design as anticancer agents.
Journal ArticleDOI
Use of chelating ligands to tune the reactive site of half-sandwich ruthenium(II)-arene anticancer complexes.
TL;DR: It is shown that the chelating ligand XY in Ru(II) anticancer complexes of the type [Ru(eta6-arene)(XY)Cl]n+ has a major influence on the rate and extent of aquation, the pKa of the aqua adduct, and the rates and selectivity of binding to nucleobases.
Journal ArticleDOI
Osmium(II) and Ruthenium(II) Arene Maltolato Complexes: Rapid Hydrolysis and Nucleobase Binding
Anna F. A. Peacock,Michael Melchart,Robert J. Deeth,Abraha Habtemariam,Simon Parsons,Peter J. Sadler +5 more
TL;DR: Insight into the aqueous solution chemistry of metal-arene complexes under biologically relevant conditions will aid the rational design of organometallic anticancer agents.